Adriana J van Ballegooijen1, Bryan Kestenbaum2, Michael C Sachs2, Ian H de Boer2, David S Siscovick3, Andrew N Hoofnagle4, Joachim H Ix5, Marjolein Visser6, Ingeborg A Brouwer6. 1. Department of Health Sciences and the EMGO Institute, VU University Amsterdam, Amsterdam, the Netherlands. Electronic address: hanne.van.ballegooijen@vu.nl. 2. Kidney Research Institute, Division of Nephrology, University of Washington, Seattle, Washington. 3. Departments of Medicine and Epidemiology, Cardiovascular Health Research Unit, University of Washington, Seattle, Washington. 4. Department of Laboratory Medicine and Medicine, University of Washington, Seattle, Washington. 5. Department of Medicine, University of California San Diego, and the Nephrology Section, Veterans Affairs San Diego Healthcare System, San Diego, California. 6. Department of Health Sciences and the EMGO Institute, VU University Amsterdam, Amsterdam, the Netherlands.
Abstract
OBJECTIVES: This study investigated whether lower 25-hydroxyvitamin D and higher parathyroid hormone concentrations are associated with incident hypertension. BACKGROUND: Disturbances in vitamin D metabolism are plausibly related to hypertension. METHODS: MESA (Multi-Ethnic Study of Atherosclerosis) is a community-based, prospective cohort with baseline measurements obtained between 2000 and 2002. We studied 3,002 men and women free of prevalent cardiovascular disease and hypertension, age 45 to 84 years at baseline. Serum 25-hydroxyvitamin D and intact parathyroid hormone were measured from previously frozen baseline samples using liquid chromatography-mass spectroscopy and a 2-site immunoassay, respectively. We used a complementary log-log model with interval censoring to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) for 25-hydroxyvitamin D and parathyroid hormone concentrations with incident hypertension through 2010. RESULTS: During a median follow-up of 9.0 years, 41% of the cohort (n = 1,229) developed hypertension. Mean serum 25-hydroxyvitamin D was 26.3 ± 11.2 ng/ml and mean parathyroid hormone was 41.2 ± 17.3 pg/ml. Compared with 25-hydroxyvitamin D ≥30 ng/ml, 25-hydroxyvitamin D <20 ng/ml was associated with a greater hypertension risk (HR: 1.28 [95% CI: 1.09 to 1.50]), although the association was attenuated and not statistically significant after adjusting for potential confounders (HR: 1.13 [95% CI: 0.96 to 1.33]). Compared with parathyroid hormone <33 pg/ml, parathyroid hormone ≥65 pg/ml was associated with a significantly greater risk of hypertension (HR: 1.27 [95% CI: 1.01 to 1.59]) after adjusting for potential confounders. CONCLUSIONS: Lower 25-hydroxyvitamin D concentrations were not associated with a greater risk of incident hypertension. Higher serum parathyroid hormone concentrations showed a significant, but statistically marginal, relationship to the development of hypertension. These findings will require further confirmation. (Multi-Ethnic Study of Atherosclerosis; NCT00005487).
OBJECTIVES: This study investigated whether lower 25-hydroxyvitamin D and higher parathyroid hormone concentrations are associated with incident hypertension. BACKGROUND: Disturbances in vitamin D metabolism are plausibly related to hypertension. METHODS:MESA (Multi-Ethnic Study of Atherosclerosis) is a community-based, prospective cohort with baseline measurements obtained between 2000 and 2002. We studied 3,002 men and women free of prevalent cardiovascular disease and hypertension, age 45 to 84 years at baseline. Serum 25-hydroxyvitamin D and intact parathyroid hormone were measured from previously frozen baseline samples using liquid chromatography-mass spectroscopy and a 2-site immunoassay, respectively. We used a complementary log-log model with interval censoring to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) for 25-hydroxyvitamin D and parathyroid hormone concentrations with incident hypertension through 2010. RESULTS: During a median follow-up of 9.0 years, 41% of the cohort (n = 1,229) developed hypertension. Mean serum 25-hydroxyvitamin D was 26.3 ± 11.2 ng/ml and mean parathyroid hormone was 41.2 ± 17.3 pg/ml. Compared with 25-hydroxyvitamin D ≥30 ng/ml, 25-hydroxyvitamin D <20 ng/ml was associated with a greater hypertension risk (HR: 1.28 [95% CI: 1.09 to 1.50]), although the association was attenuated and not statistically significant after adjusting for potential confounders (HR: 1.13 [95% CI: 0.96 to 1.33]). Compared with parathyroid hormone <33 pg/ml, parathyroid hormone ≥65 pg/ml was associated with a significantly greater risk of hypertension (HR: 1.27 [95% CI: 1.01 to 1.59]) after adjusting for potential confounders. CONCLUSIONS: Lower 25-hydroxyvitamin D concentrations were not associated with a greater risk of incident hypertension. Higher serum parathyroid hormone concentrations showed a significant, but statistically marginal, relationship to the development of hypertension. These findings will require further confirmation. (Multi-Ethnic Study of Atherosclerosis; NCT00005487).
Authors: Bryan Kestenbaum; Ronit Katz; Ian de Boer; Andy Hoofnagle; Mark J Sarnak; Michael G Shlipak; Nancy S Jenny; David S Siscovick Journal: J Am Coll Cardiol Date: 2011-09-27 Impact factor: 24.094
Authors: Jeffrey L Anderson; Ryan C Vanwoerkom; Benjamin D Horne; Tami L Bair; Heidi T May; Donald L Lappé; Joseph B Muhlestein Journal: Am Heart J Date: 2011-08 Impact factor: 4.749
Authors: Songcang Chen; Christopher S Law; Christopher L Grigsby; Keith Olsen; Ting-Ting Hong; Yan Zhang; Yerem Yeghiazarians; David G Gardner Journal: Circulation Date: 2011-09-26 Impact factor: 29.690
Authors: Karen L Margolis; Lisa W Martin; Roberta M Ray; Tessa J Kerby; Matthew A Allison; J David Curb; Theodore A Kotchen; Simin Liu; Sylvia Wassertheil-Smoller; Joann E Manson Journal: Am J Epidemiol Date: 2011-11-29 Impact factor: 4.897
Authors: Andreas Tomaschitz; Stefan Pilz; Eberhard Ritz; Tanja Grammer; Christiane Drechsler; Bernhard O Boehm; Winfried März Journal: Clin Chim Acta Date: 2010-06-01 Impact factor: 3.786
Authors: Yanbin Dong; Inger S Stallmann-Jorgensen; Norman K Pollock; Ryan A Harris; Daniel Keeton; Ying Huang; Ke Li; Reda Bassali; De-huang Guo; Jeffrey Thomas; Gary L Pierce; Jennifer White; Michael F Holick; Haidong Zhu Journal: J Clin Endocrinol Metab Date: 2010-07-21 Impact factor: 5.958
Authors: Rupal Mehta; Alexander Hodakowski; Xuan Cai; Kris E Lee; Bryan R Kestenbaum; Ian H de Boer; Amani Fawzi; Tien Yin Wong; Joachim Ix; Barbara Klein; Ronald Klein; Tamara Isakova Journal: Ophthalmic Epidemiol Date: 2017-04-12 Impact factor: 1.648
Authors: Fahim Abbasi; David Feldman; Michael P Caulfield; Feras M Hantash; Gerald M Reaven Journal: Am J Hypertens Date: 2014-08-19 Impact factor: 2.689
Authors: Lu Yao; Aaron R Folsom; James S Pankow; Elizabeth Selvin; Erin D Michos; Alvaro Alonso; Weihong Tang; Pamela L Lutsey Journal: J Hypertens Date: 2016-02 Impact factor: 4.844
Authors: Anand Vaidya; Gary C Curhan; Julie M Paik; Henry Kronenberg; Eric N Taylor Journal: J Clin Endocrinol Metab Date: 2015-04-17 Impact factor: 5.958